- Home
- Special Topics
- Disease areas
- Diabetes
This page brings together the Agency's latest information on diabetes.
It lists:
the ten newest and recently updated medicines authorised for the treatment of diabetes in the European Union (EU);
the most recent opinions on anti-diabetes medicines that are pending authorisation by the European Commission (EC);
the latest diabetes-related news and press releases;
the Agency's events on diabetes-related topics.
New and recently updated medicines
-
14/09/2012
human
-
14/09/2012
human
-
20/03/2013
human
-
16/11/2008
human
-
10/05/2011
human
-
14/09/2012
human
-
21/03/2013
human
-
20/03/2013
human
-
02/04/2013
human
-
10/04/2012
human
Opinions pending EC decision
-
17/01/2013
human
-
17/01/2013
human
-
20/09/2012
human
-
19/04/2012
human
News
26/03/2013
European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes
The European Medicines Agency is investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis (inflammation of the pancreas) and precancerous cellular changes called pancreatic-duct metaplasia in patients with type-2 diabetes treated with so-called GLP-1-based therapies (glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors). ... Read more
13/03/2013
14 March 2013: World Kidney Day: ‘Acute kidney injury: stop kidney attack!'
The European Medicines Agency supports World Kidney Day, which is taking place on Thursday 14 March 2013. ... Read more
18/01/2013
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013
This page provides an overview of the opinions adopted at the January 2013 meeting of the CHMP and other important outcomes. ... Read more
14/12/2012
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2012
This page provides an overview of the opinions adopted at the December 2012 meeting of the CHMP and other important outcomes. ... Read more
27/11/2012
Marvel LifeSciences Ltd withdraws its marketing-authorisation applications for Solumarv, Isomarv medium and Combimarv (human insulin)
The European Medicines Agency has been formally notified by Marvel LifeScience Ltd of its decision to withdraw its applications for centralised marketing authorisations for the medicines Solumarv, Isomarv medium and Combimarv (human insulin), all 100 international units (IU)/ml solution for injection. ... Read more
16/11/2012
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2012
This page provides an overview of the opinions adopted at the November 2012 meeting of the CHMP and other important outcomes. ... Read more
13/11/2012
World Diabetes Day: 14 November 2012
The European Medicines Agency supports World Diabetes Day, which is taking place on Wednesday 14 November 2012. ... Read more
19/10/2012
European Medicines Agency recommends approval of first higher-strength insulin for treatment of patients with diabetes mellitus in the EU
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a recommendation to give marketing authorisation to insulin degludec, a new basal analogue insulin for the treatment of diabetes mellitus in adults. ... Read more
19/10/2012
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2012
At the start of its October 2012 meeting, the CHMP elected Dr Ian Hudson as its new vice-chair for a three-year mandate. ... Read more
21/09/2012
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2012
At the start of its September 2012 meeting, the Committee for Medicinal Products for Human Use (CHMP) elected Tomas Salmonson as its new chair for a three-year mandate. ... Read more
Events
25/02/2013
EMA
Workshop on paediatric investigation plans in type-2 diabetes mellitus
This workshop focuses on aspects of paediatric clinical trials in type-2 diabetes mellitus (T2DM). Experts in the field, together with regulators and the pharmaceutical industry discuss suitable inclusion criteria, outcome measures and study designs in paediatric investigation plans in T2DM and approaches to enhance trial feasibility. Expressions of interest to be sent by 11/02/2013. Registration by invitation only. ... Read more
17/04/2009
PDCO
Meeting of the paediatric diabetes mellitus expert group
This meeting is aiming to identify the best possible research approaches for new medication in the field of diabetes in childhood and adolescence. Participants have been sent the questions in advance, with a request to submit short answers in writing, to be discussed during the meeting. ... Read more